🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jaime Andrade‐Villanueva

Universidad de Guadalajara

ORCID: 0000-0003-1948-655X

Also affiliated with Hospital Universitario de Guadalajara, Hospital Civil de Guadalajara

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial”.

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(20)30558-0

N/A

5.1DataRank · unranked

225 citations

Thomas C. Hanff, Preethi William, Nancy K. Sweitzer, Nelson R. Rosado‐Santander, C. Medina +28 more

Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol

Journal of Clinical Hypertension(2020)10.1111/jch.14011

N/A

1.1DataRank · unranked

19 citations

Thomas C. Hanff, Vicente Corrales‐Medina, Preethi William, Nicolás Renna, Nelson R. Rosado‐Santander +22 more

Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

The Lancet HIV(2024)10.1016/s2352-3018(24)00089-4

N/A

1.0DataRank · unranked

31 citations

Simone Jacoby, Margaret Borok, Nnakelu Eriobu, Richard Kaplan, Nagalingeswaran Kumarasamy +32 more

A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study

Clinical Infectious Diseases(2025)10.1093/cid/ciaf346

N/A

0.165DataRank · unranked

2 citations

Margaret Borok, Nnakelu Eriobu, Richard Kaplan, Nagalingeswaran Kumarasamy, Anchalee Avihingsanon +44 more